Q-omics provides the consensus-scored IFNA1 profile across patient tissues and cancer cell-line models. IFNA1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, IFNA1 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, IFNA1 RNA expression shows 6,774 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, HNSC, and STAD as cancer lineages where IFNA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNA1 survival associations across molecular data types. IFNA1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNA1 RNA expression–survival associations across cancer types. High IFNA1 expression shows unfavorable associations in LUAD, ACC, UCEC, COAD and READ, but favorable associations in THCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for IFNA1 RNA expression.
This table summarizes IFNA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNA1 shows lower tumor expression in PRAD and higher tumor expression in HNSC, THCA and KIRP. The HNSC box plot shows higher IFNA1 RNA expression in tumor versus normal tissue (log2 FC = +0.146, t-test p < 0.001).
This table shows molecular features associated with IFNA1 in patient tissues and cancer cell lines. In patient samples, IFNA1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, IFNA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
